Research ArticleAccepted Article
Effectiveness of Tocilizumab in Patients With Rheumatoid Arthritis is Unaffected by Comorbidity Burden or Obesity: Data From a US Registry
Dimitrios A. Pappas, Carol J. Etzel, Margaux Crabtree, Taylor Blachley, Jennie Best, Steve Zlotnick and Joel M. Kremer
The Journal of Rheumatology January 2020, jrheum.190282; DOI: https://doi.org/10.3899/jrheum.190282
Dimitrios A. Pappas
Columbia University, New York, NY, USA; Corrona, LLC, Waltham, MA, USA; Genentech, Inc., South San Francisco, CA, USA; Albany Medical College and The Center for Rheumatology, Albany, NY, USA. Funding Source: This study is sponsored by Corrona, LLC. Corrona, LLC has been supported through contracted subscriptions in the last two years by AbbVie, Amgen, Bristol-Myers Squibb, Crescendo, Eli Lilly and Company, Genentech, GSK, Horizon Pharma USA, Janssen, Momenta Pharmaceuticals, Novartis, Pfizer, Roche and UCB. The study design and conduct were the result of a collaborative effort between Corrona, LLC and Genentech, Inc., and financial support for the study was provided by Genentech, Inc. Genentech, Inc. participated in the interpretation of data, review, and approval of the manuscript. All authors had full access to all of the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analysis. Conflict of interest: D.A. Pappas is an employee of Corrona, LLC, a consultant for AbbVie and has received grant support from AbbVie; C.J. Etzel is an employee and shareholder of Corrona, LLC, and is a member of an advisory board for Merck; M. Crabtree is an employee of Corrona, LLC. J. Best and S. Zlotnick are employees and shareholders of Genentech, Inc. J.M. Kremer is an employee and shareholder of Corrona, LLC, and a consultant for AbbVie, Amgen, Bristol- Myers Squibb, Genentech, GlaxoSmithKline, Lilly, Pfizer, Regeneron and Sanofi. Corresponding Author: Dimitrios A. Pappas Columbia University, College of Physicians and Surgeons New York Presbyterian Hospital P&S Building, Suite 10-455 New York, NY 10032. Email: dpappas@corrona.org
Carol J. Etzel
Columbia University, New York, NY, USA; Corrona, LLC, Waltham, MA, USA; Genentech, Inc., South San Francisco, CA, USA; Albany Medical College and The Center for Rheumatology, Albany, NY, USA. Funding Source: This study is sponsored by Corrona, LLC. Corrona, LLC has been supported through contracted subscriptions in the last two years by AbbVie, Amgen, Bristol-Myers Squibb, Crescendo, Eli Lilly and Company, Genentech, GSK, Horizon Pharma USA, Janssen, Momenta Pharmaceuticals, Novartis, Pfizer, Roche and UCB. The study design and conduct were the result of a collaborative effort between Corrona, LLC and Genentech, Inc., and financial support for the study was provided by Genentech, Inc. Genentech, Inc. participated in the interpretation of data, review, and approval of the manuscript. All authors had full access to all of the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analysis. Conflict of interest: D.A. Pappas is an employee of Corrona, LLC, a consultant for AbbVie and has received grant support from AbbVie; C.J. Etzel is an employee and shareholder of Corrona, LLC, and is a member of an advisory board for Merck; M. Crabtree is an employee of Corrona, LLC. J. Best and S. Zlotnick are employees and shareholders of Genentech, Inc. J.M. Kremer is an employee and shareholder of Corrona, LLC, and a consultant for AbbVie, Amgen, Bristol- Myers Squibb, Genentech, GlaxoSmithKline, Lilly, Pfizer, Regeneron and Sanofi. Corresponding Author: Dimitrios A. Pappas Columbia University, College of Physicians and Surgeons New York Presbyterian Hospital P&S Building, Suite 10-455 New York, NY 10032. Email: dpappas@corrona.org
Margaux Crabtree
Columbia University, New York, NY, USA; Corrona, LLC, Waltham, MA, USA; Genentech, Inc., South San Francisco, CA, USA; Albany Medical College and The Center for Rheumatology, Albany, NY, USA. Funding Source: This study is sponsored by Corrona, LLC. Corrona, LLC has been supported through contracted subscriptions in the last two years by AbbVie, Amgen, Bristol-Myers Squibb, Crescendo, Eli Lilly and Company, Genentech, GSK, Horizon Pharma USA, Janssen, Momenta Pharmaceuticals, Novartis, Pfizer, Roche and UCB. The study design and conduct were the result of a collaborative effort between Corrona, LLC and Genentech, Inc., and financial support for the study was provided by Genentech, Inc. Genentech, Inc. participated in the interpretation of data, review, and approval of the manuscript. All authors had full access to all of the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analysis. Conflict of interest: D.A. Pappas is an employee of Corrona, LLC, a consultant for AbbVie and has received grant support from AbbVie; C.J. Etzel is an employee and shareholder of Corrona, LLC, and is a member of an advisory board for Merck; M. Crabtree is an employee of Corrona, LLC. J. Best and S. Zlotnick are employees and shareholders of Genentech, Inc. J.M. Kremer is an employee and shareholder of Corrona, LLC, and a consultant for AbbVie, Amgen, Bristol- Myers Squibb, Genentech, GlaxoSmithKline, Lilly, Pfizer, Regeneron and Sanofi. Corresponding Author: Dimitrios A. Pappas Columbia University, College of Physicians and Surgeons New York Presbyterian Hospital P&S Building, Suite 10-455 New York, NY 10032. Email: dpappas@corrona.org
Taylor Blachley
Columbia University, New York, NY, USA; Corrona, LLC, Waltham, MA, USA; Genentech, Inc., South San Francisco, CA, USA; Albany Medical College and The Center for Rheumatology, Albany, NY, USA. Funding Source: This study is sponsored by Corrona, LLC. Corrona, LLC has been supported through contracted subscriptions in the last two years by AbbVie, Amgen, Bristol-Myers Squibb, Crescendo, Eli Lilly and Company, Genentech, GSK, Horizon Pharma USA, Janssen, Momenta Pharmaceuticals, Novartis, Pfizer, Roche and UCB. The study design and conduct were the result of a collaborative effort between Corrona, LLC and Genentech, Inc., and financial support for the study was provided by Genentech, Inc. Genentech, Inc. participated in the interpretation of data, review, and approval of the manuscript. All authors had full access to all of the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analysis. Conflict of interest: D.A. Pappas is an employee of Corrona, LLC, a consultant for AbbVie and has received grant support from AbbVie; C.J. Etzel is an employee and shareholder of Corrona, LLC, and is a member of an advisory board for Merck; M. Crabtree is an employee of Corrona, LLC. J. Best and S. Zlotnick are employees and shareholders of Genentech, Inc. J.M. Kremer is an employee and shareholder of Corrona, LLC, and a consultant for AbbVie, Amgen, Bristol- Myers Squibb, Genentech, GlaxoSmithKline, Lilly, Pfizer, Regeneron and Sanofi. Corresponding Author: Dimitrios A. Pappas Columbia University, College of Physicians and Surgeons New York Presbyterian Hospital P&S Building, Suite 10-455 New York, NY 10032. Email: dpappas@corrona.org
Jennie Best
Columbia University, New York, NY, USA; Corrona, LLC, Waltham, MA, USA; Genentech, Inc., South San Francisco, CA, USA; Albany Medical College and The Center for Rheumatology, Albany, NY, USA. Funding Source: This study is sponsored by Corrona, LLC. Corrona, LLC has been supported through contracted subscriptions in the last two years by AbbVie, Amgen, Bristol-Myers Squibb, Crescendo, Eli Lilly and Company, Genentech, GSK, Horizon Pharma USA, Janssen, Momenta Pharmaceuticals, Novartis, Pfizer, Roche and UCB. The study design and conduct were the result of a collaborative effort between Corrona, LLC and Genentech, Inc., and financial support for the study was provided by Genentech, Inc. Genentech, Inc. participated in the interpretation of data, review, and approval of the manuscript. All authors had full access to all of the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analysis. Conflict of interest: D.A. Pappas is an employee of Corrona, LLC, a consultant for AbbVie and has received grant support from AbbVie; C.J. Etzel is an employee and shareholder of Corrona, LLC, and is a member of an advisory board for Merck; M. Crabtree is an employee of Corrona, LLC. J. Best and S. Zlotnick are employees and shareholders of Genentech, Inc. J.M. Kremer is an employee and shareholder of Corrona, LLC, and a consultant for AbbVie, Amgen, Bristol- Myers Squibb, Genentech, GlaxoSmithKline, Lilly, Pfizer, Regeneron and Sanofi. Corresponding Author: Dimitrios A. Pappas Columbia University, College of Physicians and Surgeons New York Presbyterian Hospital P&S Building, Suite 10-455 New York, NY 10032. Email: dpappas@corrona.org
Steve Zlotnick
Columbia University, New York, NY, USA; Corrona, LLC, Waltham, MA, USA; Genentech, Inc., South San Francisco, CA, USA; Albany Medical College and The Center for Rheumatology, Albany, NY, USA. Funding Source: This study is sponsored by Corrona, LLC. Corrona, LLC has been supported through contracted subscriptions in the last two years by AbbVie, Amgen, Bristol-Myers Squibb, Crescendo, Eli Lilly and Company, Genentech, GSK, Horizon Pharma USA, Janssen, Momenta Pharmaceuticals, Novartis, Pfizer, Roche and UCB. The study design and conduct were the result of a collaborative effort between Corrona, LLC and Genentech, Inc., and financial support for the study was provided by Genentech, Inc. Genentech, Inc. participated in the interpretation of data, review, and approval of the manuscript. All authors had full access to all of the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analysis. Conflict of interest: D.A. Pappas is an employee of Corrona, LLC, a consultant for AbbVie and has received grant support from AbbVie; C.J. Etzel is an employee and shareholder of Corrona, LLC, and is a member of an advisory board for Merck; M. Crabtree is an employee of Corrona, LLC. J. Best and S. Zlotnick are employees and shareholders of Genentech, Inc. J.M. Kremer is an employee and shareholder of Corrona, LLC, and a consultant for AbbVie, Amgen, Bristol- Myers Squibb, Genentech, GlaxoSmithKline, Lilly, Pfizer, Regeneron and Sanofi. Corresponding Author: Dimitrios A. Pappas Columbia University, College of Physicians and Surgeons New York Presbyterian Hospital P&S Building, Suite 10-455 New York, NY 10032. Email: dpappas@corrona.org
Joel M. Kremer
Columbia University, New York, NY, USA; Corrona, LLC, Waltham, MA, USA; Genentech, Inc., South San Francisco, CA, USA; Albany Medical College and The Center for Rheumatology, Albany, NY, USA. Funding Source: This study is sponsored by Corrona, LLC. Corrona, LLC has been supported through contracted subscriptions in the last two years by AbbVie, Amgen, Bristol-Myers Squibb, Crescendo, Eli Lilly and Company, Genentech, GSK, Horizon Pharma USA, Janssen, Momenta Pharmaceuticals, Novartis, Pfizer, Roche and UCB. The study design and conduct were the result of a collaborative effort between Corrona, LLC and Genentech, Inc., and financial support for the study was provided by Genentech, Inc. Genentech, Inc. participated in the interpretation of data, review, and approval of the manuscript. All authors had full access to all of the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analysis. Conflict of interest: D.A. Pappas is an employee of Corrona, LLC, a consultant for AbbVie and has received grant support from AbbVie; C.J. Etzel is an employee and shareholder of Corrona, LLC, and is a member of an advisory board for Merck; M. Crabtree is an employee of Corrona, LLC. J. Best and S. Zlotnick are employees and shareholders of Genentech, Inc. J.M. Kremer is an employee and shareholder of Corrona, LLC, and a consultant for AbbVie, Amgen, Bristol- Myers Squibb, Genentech, GlaxoSmithKline, Lilly, Pfizer, Regeneron and Sanofi. Corresponding Author: Dimitrios A. Pappas Columbia University, College of Physicians and Surgeons New York Presbyterian Hospital P&S Building, Suite 10-455 New York, NY 10032. Email: dpappas@corrona.org
Published eLetters
eLetters are comments published online only and are not peer-reviewed. Publication of eLetter submissions is not guaranteed, and all submissions are reviewed and edited at the discretion of The Journal's staff.
If you wish to publish Letters to the Editor or Correspondence, please submit through our online submission system ScholarOne Manuscripts.
Jump to comment:
No eLetters have been published for this article.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 3
1 Mar 2024
Accepted manuscript
Effectiveness of Tocilizumab in Patients With Rheumatoid Arthritis is Unaffected by Comorbidity Burden or Obesity: Data From a US Registry
Dimitrios A. Pappas, Carol J. Etzel, Margaux Crabtree, Taylor Blachley, Jennie Best, Steve Zlotnick, Joel M. Kremer
The Journal of Rheumatology Jan 2020, jrheum.190282; DOI: 10.3899/jrheum.190282
Accepted manuscript
Effectiveness of Tocilizumab in Patients With Rheumatoid Arthritis is Unaffected by Comorbidity Burden or Obesity: Data From a US Registry
Dimitrios A. Pappas, Carol J. Etzel, Margaux Crabtree, Taylor Blachley, Jennie Best, Steve Zlotnick, Joel M. Kremer
The Journal of Rheumatology Jan 2020, jrheum.190282; DOI: 10.3899/jrheum.190282